[go: up one dir, main page]

PE20130812A1 - Combinacion de inhibidor de xantina oxidasa y antagonistas del receptor de angiotensina ii - Google Patents

Combinacion de inhibidor de xantina oxidasa y antagonistas del receptor de angiotensina ii

Info

Publication number
PE20130812A1
PE20130812A1 PE2012002151A PE2012002151A PE20130812A1 PE 20130812 A1 PE20130812 A1 PE 20130812A1 PE 2012002151 A PE2012002151 A PE 2012002151A PE 2012002151 A PE2012002151 A PE 2012002151A PE 20130812 A1 PE20130812 A1 PE 20130812A1
Authority
PE
Peru
Prior art keywords
combination
angiotensin
xanthine oxidase
receptor antagonists
oxidase inhibitor
Prior art date
Application number
PE2012002151A
Other languages
English (en)
Inventor
Francesco Melani
Sandro Giuliani
Carlo Alberto Maggi
Original Assignee
Menarini Int Operations Lu Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42753377&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20130812(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Menarini Int Operations Lu Sa filed Critical Menarini Int Operations Lu Sa
Publication of PE20130812A1 publication Critical patent/PE20130812A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Emergency Medicine (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

REFERIDA A UNA COMBINACION QUE COMPRENDE: a) UN INHIBIDOR DE LA XANTINA OXIDASA TAL COMO FEBUXOSTAT, SALES FARMACEUTICAMENTE ACEPTABLES DEL MISMO O SUS FORMAS POLIMORFICAS Y b) UN ANTAGONISTA DEL RECEPTOR DE ANGIOTENSINA II TAL COMO OLMESARTAN MEDOXOMIL O SALES FARMACEUTICAMENTE ACEPTABLES DEL MISMO, DONDE LA RELACION EN PESO ENTRE EL PRINCIPIO a Y b ESTA COMPRENDIDA ENTRE 0,1 Y 200. DICHA COMBINACION ES UTIL EN EL TRATAMIENTO DE LA HIPERTENSION SOLA O COMBINADA CON HIPERURICEMIA Y/O HIPERGLICEMIA U OTRAS ALTERACIONES METABOLICAS
PE2012002151A 2010-05-10 2011-05-09 Combinacion de inhibidor de xantina oxidasa y antagonistas del receptor de angiotensina ii PE20130812A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ITRM2010A000232A IT1400311B1 (it) 2010-05-10 2010-05-10 Associazione di inibitori della xantina ossidasi e antagonisti del recettore dell'angiotensina ii e loro uso.

Publications (1)

Publication Number Publication Date
PE20130812A1 true PE20130812A1 (es) 2013-08-08

Family

ID=42753377

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2012002151A PE20130812A1 (es) 2010-05-10 2011-05-09 Combinacion de inhibidor de xantina oxidasa y antagonistas del receptor de angiotensina ii

Country Status (24)

Country Link
US (1) US20130131128A1 (es)
EP (1) EP2568982B1 (es)
JP (1) JP2013526503A (es)
KR (1) KR20130101447A (es)
CN (1) CN103037861A (es)
AR (1) AR081376A1 (es)
AU (1) AU2011252151A1 (es)
BR (1) BR112012028887A2 (es)
CA (1) CA2798573A1 (es)
CL (1) CL2012003143A1 (es)
CO (1) CO6640306A2 (es)
EA (1) EA201201528A1 (es)
EC (2) ECSP12012331A (es)
IL (1) IL222927A0 (es)
IT (1) IT1400311B1 (es)
MA (1) MA34297B1 (es)
MX (1) MX2012013054A (es)
NZ (1) NZ603414A (es)
PE (1) PE20130812A1 (es)
PH (1) PH12012502198A1 (es)
SG (1) SG185474A1 (es)
TW (1) TW201206432A (es)
WO (1) WO2011141431A1 (es)
ZA (1) ZA201209295B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3028371B1 (fr) * 2014-11-06 2016-11-18 Bull Sas Procede de surveillance et de controle deportes d'un cluster utilisant un reseau de communication de type infiniband et programme d'ordinateur mettant en oeuvre ce procede
JP2018135278A (ja) * 2017-02-20 2018-08-30 株式会社スタージェン 循環器疾患及び／又はミトコンドリア病の改善用医薬
KR102284764B1 (ko) 2020-07-08 2021-08-04 주식회사 우드메탈 멀티빔구조를 통한 부속의 결속이 용이한 칸막이

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0513379T3 (da) 1990-11-30 1996-09-30 Teijin Ltd 2-Arylthiazolderivater og farmaceutisk præparat indeholdende sådanne
CA2229000C (en) 1991-02-21 2002-04-09 Sankyo Company, Limited 1-biphenylimidazole derivatives, their preparation and their therapeutic use
SK287928B6 (sk) 1998-06-19 2012-04-03 Teijin Pharma Limited Polymorphic modifications of 2-(3-cyano-4-isobutyloxyphenyl)-4- methyl-5-thiazole-carboxylic acid and processes for the preparation thereof
SK5992003A3 (en) 2000-11-21 2003-11-04 Sankyo Co Medicinal composition comprising an angiotensin II receptor antagonist and one or more diuretics and use thereof
US20040122067A1 (en) 2002-12-20 2004-06-24 Lin Zhao Treatment of chronic heart failure
PL377344A1 (pl) 2003-01-31 2006-01-23 Sankyo Company, Limited Lekarstwo do profilaktyki i leczenia miażdżycy tętnic i nadciśnienia
WO2005027887A2 (en) * 2003-09-17 2005-03-31 Cardimone Pharma Corporation Methods and compositions for improving endothelial function
WO2007019153A2 (en) * 2005-08-03 2007-02-15 Tap Pharmaceutical Products, Inc. Methods for treating hypertension
WO2007062028A2 (en) 2005-11-21 2007-05-31 Tap Pharmaceutical Products, Inc. Treatment of qt interval prolongation and diseases associated therewith
AU2007323919A1 (en) 2006-11-13 2008-05-29 Takeda Pharmaceuticals U.S.A., Inc. Methods for preserving renal function using xanthine oxidoreductase inhibitors

Also Published As

Publication number Publication date
EA201201528A1 (ru) 2013-04-30
CO6640306A2 (es) 2013-03-22
EP2568982B1 (en) 2014-04-02
PH12012502198A1 (en) 2013-02-25
IL222927A0 (en) 2012-12-31
CL2012003143A1 (es) 2013-06-21
CA2798573A1 (en) 2011-11-17
BR112012028887A2 (pt) 2016-07-26
IT1400311B1 (it) 2013-05-24
SG185474A1 (en) 2012-12-28
MA34297B1 (fr) 2013-06-01
JP2013526503A (ja) 2013-06-24
ECSP12012332A (es) 2013-02-28
US20130131128A1 (en) 2013-05-23
KR20130101447A (ko) 2013-09-13
TW201206432A (en) 2012-02-16
ITRM20100232A1 (it) 2011-11-11
ZA201209295B (en) 2013-08-28
NZ603414A (en) 2014-03-28
WO2011141431A1 (en) 2011-11-17
MX2012013054A (es) 2013-03-05
ECSP12012331A (es) 2013-02-28
AR081376A1 (es) 2012-08-29
AU2011252151A1 (en) 2012-11-29
CN103037861A (zh) 2013-04-10
EP2568982A1 (en) 2013-03-20

Similar Documents

Publication Publication Date Title
IL264441A (en) Novel modified release dosage forms of xanthine oxidoreductase inhibitor or xanthine oxidase inhibitors
UY33379A (es) Compuestos de morfolina
ECSP11011294A (es) Compuestos de anillo fusionados y su uso
UY33271A (es) Inhibidores heterocíclicos de los receptores de histamina para el tratamiento de una enfermedad
ECSP12012317A (es) Marcadores predictivos útiles en el tratamiento del síndrome frágil x (fxs)
PE20140040A1 (es) Composicion farmaceutica que comprende un inhibidor de la actividad de mek
UY33272A (es) Inhibidores heterocíclicos de los receptores de histamina para el tratamiento de una enfermedad
CL2010001361A1 (es) Compuestos derivados de piperidin-carboxamida, inhibidores de renina; composicion farmaceutica que los comprende; y uso en el tratamiento o prevencion de una enfermedad circulatoria, hipertension y/o diversos daños organicos atribuibles a la hipertension.
MX381819B (es) Derivados de heterociclico opcionalmente condensados de pirimidina útiles para el tratamiento de enfermedades inflamatorias, metabólicas oncológicas y autoinmunitarias.
MX385616B (es) Inhibidores de cdk
CR20110421A (es) Agonistas y antagonistas del receptor de s1p, y métodos de uso de los mismos
CL2008000418A1 (es) Uso de un antagonista de la il-23 para el tratamiento de una infeccion fungica.
CL2012002904A1 (es) Combinación o composición farmacéutica que comprende un inhibidor de la señalización de células y/o de la angiogénesis y un inhibidor de la quinasa aurora (aki); kit faramcéutico que la comprende; su uso en el tratamiento de enfermedades oncológicas y fibróticas; y compuestos derivados de indol y pirimidina sustituidos.
CL2013000378A1 (es) Combinacion farmaceutica que comprende un farmaco antipsicotico atipico, tal como risperidona y olanzapina, entre otros, y un compuesto derivado de piperazina-fenil-metanona, antagonista del receptor de glyt1; método de tratamiento; y su uso para el tratamiento de sintomas positivos y negativos de la esquizofrenia.
UY34436A (es) Metodo de control del peso
PE20141584A1 (es) Uso de un inhibidor de aromatasa para el tratamiento del hipogonadismo y enfermedades relacionadas
PE20130812A1 (es) Combinacion de inhibidor de xantina oxidasa y antagonistas del receptor de angiotensina ii
CL2012002543A1 (es) Composicion endoparasiticida que comprende una combinacion de un compuesto de formula (i) derivado de amidoacetonitrilo y abamectina; y su uso para el control de endoparasitos, en particular helmintos.
AR065077A1 (es) Composiciones farmaceuticas y metodos para utilizar temozolomida e inhibidores de quinasa multidirigidos
CR20120617A (es) Combinación de inhibidores de xantna oxidasa y antagonistas del receptor de angiotensina ii y su uso
SV2010003702A (es) Asociacion de la dronedarona con al menos un diuretico, su aplicacion en terapeutica
CY1116283T1 (el) Δοσολογια μοναδας apadenoson
CL2012003661A1 (es) Composición farmacéutica de liberación sostenida que comprende un compuesto derivado de 2-feniltiazol; y uso en el tratamiento o prevención de la hipertensión o la presión sanguínea alta normal.
CL2013003083A1 (es) Compuestos derivados de sulfonamido bencil oxadiazol con actividad antagonista del receptor npy y5; composición farmacéutica que los comprende; útiles en el tratamiento de la obesidad, depresión, hipertensión, insuficiencia cardiaca congestiva, trastornos del sueño, entre otros.
PA8852601A1 (es) Antagonistas del receptor de angiotensina ii

Legal Events

Date Code Title Description
FD Application declared void or lapsed